Gain Therapeutics plans Phase 2 trial of rexaceract in Parkinson's disease for Q1 2027 start

• Gain Therapeutics disclosed new long-term Phase 1b extension results for rexaceract in Parkinson’s disease, slated for poster presentation Oct. 4-8, 2026.
• Patient motor assessments remained broadly stable over a year of dosing, supporting a potential disease-modifying profile.
• Safety profile stayed consistent over 12 months, with no new signals reported in the extension period.
• Management plans to file a Phase 2 protocol with the FDA in coming weeks, targeting trial initiation in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112624), on October 01, 2026, and is solely responsible for the information contained therein.